Add like
Add dislike
Add to saved papers

Nationwide survey on cerebral amyloid angiopathy in Japan.

BACKGROUND: We conducted a nationwide survey to understand the epidemiology of cerebral amyloid angiopathy-related intracerebral hemorrhage (CAA-related ICH) and cerebral amyloid angiopathy-related inflammation/vasculitis (CAA-ri) in Japan.

METHODS: To estimate the total number and clinical features of patients with CAA-related ICH and CAA-ri between January 2012 and December 2014 and to analyze their clinical features, we sent questionnaires to randomly selected hospitals in Japan.

RESULTS: In the first survey, 2,348 of 4,657 departments responded to the questionnaire (response rate: 50.4%). The total numbers of reported patients with CAA-related ICH and CAA-ri were 1,338 and 61, respectively, and their total numbers in Japan were estimated to be 5900 (95% confidence interval (CI), 4800-7100) and 170 (95% CI, 110-220), respectively. The crude prevalence rates were 4.64 and 0.13 per 100,000 population, respectively. The clinical information of 474 patients with CAA-related ICH obtained in the second survey was as follows: (1) the average age of onset was 78.4 years; (2) the prevalence increased with age; (3) the disease was common in women; and (4) hematoma most frequently occurred in the frontal lobe. Sixteen patients with CAA-ri for whom data was collected in the second survey had the following characteristics: (1) median age of onset was 75 years, (2) cognitive impairment and headache were the most frequent initial manifestations, and (3) focal neurological signs, such as motor paresis and visual disturbance, were frequently observed during the clinical course.

CONCLUSIONS: We estimated the number of patients with CAA-related ICH and CAA-ri in Japan. This article is protected by copyright. All rights reserved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app